Lipid Sciences, Inc. (NASDAQ: LIPD) announced that the first patient in its human clinical trial had completed a series of seven procedures of plasma collection and re-infusion and the procedures were well tolerated. Additional patients have now been recruited into the trial and are undergoing the weekly procedures as planned.
